$ILMN

Meister Keith A. sold $85.2M of ILMN (indirect holdings)

Meister Keith A. sold 375,941 indirectly-held shares of ILLUMINA, INC. (ILMN) at an average of $226.74 ($224.72–$231.23, $85.24M total) across 13 trades over 2026-08-25 to 2026-08-27.

Original reporting
SEC EDGAR · Meister Keith A.
Published Aug 27, 2026, 11:35 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 27, 2026, 11:37 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ILMN
Bearish
medium confidence
Mentioned
$ILMN
Relevance
8/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ILMNBearishLow
01

Why it matters

The sizable director sale could trigger short interest and affect short‑term price dynamics.

02

Market read

Material insider sell by a director is a notable event for traders monitoring ILMN.

03

What to watch

The sale was executed via a 10b5‑1 plan, indicating pre‑planned execution rather than reaction to new information.

Relevance 8/10Novelty 8/10Timing: Filed Aug 27 2026 (Form 4 filing date)

Background

SEC Form 4 filing discloses insider transactions required by the SEC.

Company-level read

Ticker impact

$ILMNBearishMedium confidence
Context

Director Meister Keith A. sold 375,941 shares for $85.2M, reducing his stake to 1,033,910 shares.

Expected impact

Potential short-term downside of 2‑4% as market digests the sale.

Evidence & confidence

The $85M sale by a director is material and likely to be viewed negatively by investors.

Market effects

May weigh on other genomics and diagnostics stocks as investors reassess insider sentiment.

Limited to US biotech sector; no broader regional effect.

Minimal global impact beyond Illumina and its peers.

Counterpoint

Insider may be diversifying portfolio; sale does not necessarily reflect company fundamentals.

Key entities

  • Illumina, Inc.

    US‑listed genomics and diagnostics firm (ticker ILMN).

  • Meister Keith A.

    Director of Illumina who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ILMNHighAI 8/10

Illumina Q2FY26 Results: Revenue up 9.5% to $1.16 billion

Illumina reported Q2 2026 revenue of $1.16B, up 9.5% YoY, driven by NovaSeq X demand and clinical consumables growth. Non-GAAP EPS rose 10% to $1.31. The company raised full-year guidance, projecting revenue of $4.60B-$4.64B and EPS of $5.30-$5.40. Management cited strong instrument placements and cost management despite rising expenses. Illumina repurchased 0.9M shares and holds $1.17B in cash. The stock has returned 13.26% annually over 20 years, outperforming the market by 3.84%.

$ILMNHighAI 8/10

Illumina Reports Q2 2026 Results: Full Earnings Call Transcript - Illumina (NASDAQ:ILMN)

Illumina (ILMN) reported Q2 2026 revenue growth of 9.5% YoY and EPS growth of 10%, driven by strong demand for NovaSeq X. The company raised its 2026 guidance, expecting full-year organic revenue growth over 5% and mid-teens growth in clinical consumables. Strategic initiatives include expanding multi-omics capabilities and strengthening the BioInsight platform. Management emphasized cost management and confidence in long-term targets.

$BELow

Three Stocks Are Joining the S&P 500. Will They Actually Improve VOO’s Returns?

Vanguard S&P 500 ETF (VOO) will add Bloom Energy (BE), Illumina (ILMN), and another company, while removing Molson Coors (TAP), The Trade Desk (TTD), and Builders FirstSource (BLDR). BE's product revenue surged 215% due to AI demand, and ILMN raised EPS guidance. The changes have minimal impact on VOO's returns, as the fund is heavily concentrated in megacap stocks.

$ILMNHigh

Illumina Stock Climbs As Analyst Upgrades Meet S&P 500 Boost

Illumina Inc. (ILMN) shares rose 7.15% on September 15, 2026, after UBS upgraded it to Buy with a $260 price target, and Argus raised its target to $235. The company's Q2 revenue was $1.16B, with EBITDA of $354M. Illumina is also being added to the S&P 500, effective September 21, 2026, which may drive further demand. The stock trades at a P/E ratio of 38 and P/S ratio of 6.9, reflecting its growth prospects. Analysts cite revenue reacceleration, margin expansion, and clinical demand as key driv